Nextcure Stock Today
| NXTC Stock | USD 0.69 0.03 4.17% |
PerformanceVery Weak
| Odds Of DistressVery High
|
NextCure is trading at 0.69 as of the 16th of March 2025, a 4.17 percent decrease since the beginning of the trading day. The stock's open price was 0.72. NextCure has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. The performance scores are derived for the period starting the 16th of December 2024 and ending today, the 16th of March 2025. Click here to learn more.
NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. NextCure, Inc. was incorporated in 2015 and is headquartered in Beltsville, Maryland. The company has 28.01 M outstanding shares of which 59.22 K shares are now shorted by private and institutional investors with about 0.75 trading days to cover. More on NextCure
Moving against NextCure Stock
NextCure Stock Highlights
NextCure (NXTC) is traded on NASDAQ Exchange in USA. It is located in 9000 Virginia Manor Road, Beltsville, MD, United States, 20705 and employs 82 people. NextCure is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 19.29 M. NextCure conducts business under Biotechnology sector and is part of Health Care industry. The entity has 28.01 M outstanding shares of which 59.22 K shares are now shorted by private and institutional investors with about 0.75 trading days to cover.
NextCure currently holds about 185.49 M in cash with (40.8 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 6.68, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check NextCure Probability Of Bankruptcy
Ownership AllocationNextCure maintains a total of 28.01 Million outstanding shares. Over half of NextCure's outstanding shares are owned by institutional investors. These institutional investors are typically referred to as corporate investors that shop for positions in a given instrument to benefit from reduced trade commissions. Please note that no matter how many assets the company has, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check NextCure Ownership Details
NextCure Risk Profiles
Investors will always prefer to have the highest possible return on investment while minimizing volatility. NextCure market risk premium is the additional return an investor will receive from holding NextCure long position in a well-diversified portfolio.
| Risk Adjusted Performance | (0.10) | |||
| Jensen Alpha | (0.51) | |||
| Total Risk Alpha | (0.02) | |||
| Treynor Ratio | (1.68) |
NextCure Stock Against Markets
NextCure Corporate Management
| CPA CPA | Chief Officer | Profile | |
| Steven CPA | Chief Officer | Profile | |
| Sebastien Maloveste | Senior Development | Profile | |
| Sourav Kundu | Senior Manufacturing | Profile | |
| Kevin Shaw | General Counsel | Profile | |
| Michael MSBA | CEO, CoFounder | Profile | |
| Lieping MD | CoFounder Board | Profile |
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in NextCure. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. For information on how to trade NextCure Stock refer to our How to Trade NextCure Stock guide.You can also try the USA ETFs module to find actively traded Exchange Traded Funds (ETF) in USA.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of NextCure. If investors know NextCure will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about NextCure listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of NextCure is measured differently than its book value, which is the value of NextCure that is recorded on the company's balance sheet. Investors also form their own opinion of NextCure's value that differs from its market value or its book value, called intrinsic value, which is NextCure's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because NextCure's market value can be influenced by many factors that don't directly affect NextCure's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between NextCure's value and its price as these two are different measures arrived at by different means. Investors typically determine if NextCure is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, NextCure's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.